Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 6, 2006, Pages 412-417

  Saad, Sherif Y ^a   Najjar, Tawfeeg A ^a   Arafah, Maha M ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; CREATINE KINASE MB; DAUNORUBICIN; EBSELEN; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; NITRATE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; HEART MUSCLE; HEART PROTECTION; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; AZOLES; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CREATINE KINASE, MB FORM; DAUNORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INJECTIONS, SUBCUTANEOUS; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIUM; NITRATES; NITRITES; ORGANOSELENIUM COMPOUNDS; RATS; RATS, WISTAR;

ANIMALIA;

EID: 33751372282     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_523.x     Document Type: Article

References (39)

1. Ali, N., M. Yoshizumi, K. Tsuchiya, M. Kyaw, Y. Fujita, Y. Izawa, S. Abe, Y. Kanematsu, S. Kagami & T. Tamaki: Ebselen inhibits p38 mitogen-activated protein kinase-mediated endothelial cell death by hydrogen peroxide. Eur. J. Pharmacol. 2004, 485, 127-135.
2. Basser, R. L., M. M. Sobol, G. Duggan, J. Cebon, M. A. Rosenthal, G. Mihaly & M. D. Green: Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J. Clin. Oncol. 1994, 12, 1659-1666.
3. Cao, Y., R. Kennedy & V. S. Klimberg: Glutamine protects against doxorubicin-induced cardiotoxicity. J. Surg. Res. 1999, 85, 178-182.
4. Charlier, H. A. Jr., R. D. Olson, C. M. Thornock, W. K. Mercer, D. R. Olson, T. S. Broyles, D. J. Muhlestein, C. L. Larson, B. J. Cusack & S. E. Shadle: Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol. Pharmacol. 2005, 67, 1505-1512.
5. Cleeter, M. W. J., J. M. Cooper, V. M. Darley-Usmar, S. Moncada & A. H. V. Schapira: Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 1994, 345, 50-54.
6. Cusack, B. J., H. Gambliel, B. Musser, N. Hadjokas, S. E. Shadle, H. Charlier & R. D. Olson: Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemother. Pharmacol. 2006, 58, 517-526.
7. Daiber, A., M. H. Zou, M. Bachschmid & V. Ullrich: Ebselen as a peroxynitrite scavenger in vitro and ex vivo. Biochem. Pharmacol. 2000, 59, 153-160.
8. Ellman, G. L.: Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959, 82, 70-71.
9. Guerin, P. J. & E. R. Gauthier: induction of cellular necrosis by the glutathione peroxidase mimetic ebselen. J. Cell Biochem. 2003, 89, 203-211.
10. Jozsef, L. & J. G. Filep: Selenium-containing compounds attenuates peroxynitrite-mediated NF-kappa B and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic. Biol. Med. 2003, 35, 1018-1027.
11. Kaiserova, H. & E. Kvasnickova: Inhibition study of rabbit liver cytosolic reductases involved in daunorubicin toxication. J. Enzyme Inhib. Med. Chem. 2005, 20, 477-483.
12. Kalivendi, S. V., S. Kotamraju, H. Zhao, J. Joseph & B. Kalyanaraman: Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 2001, 276, 47266-47276.
13. Kalyanaraman, B., J. Joseph, S. Kalivendi, S. Wang, E. Konorev & S. Kotamraju: Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell Biochem. 2002, 234/235, 119-124.
14. Kluza, J., P. Marchetti, M. A. Gallego, S. Lancel, C. Fournier, A. Loyens, J. C. Beauvillain & C. Bailly: Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004, 23, 7018-7030.
15. Mihm, M. J., F. Yu, D. M. Weinstein, P. J. Reiser & J. A. Bauer: Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Brit. J. Pharmacol. 2002, 135, 581-588.
16. Miranda, K. M., M. G. Espey & D. A. Wink: A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5, 62-71.
17. Morin, D., R. Zini, H. Ligeret, W. Neckameyer, S. Labidalle & J. P. Tillement: dual effect of ebselen on mitochondrial permeability transition. Biochem. Pharmacol. 2003, 65, 1643-1651.
18. Nagi, M. N., J. C. Laguna, L. Cook & D. L. Cinti: Disruption of rat hepatic microsomal electron transport chains by the selenium-containing anti-inflammatory agent Ebselen. Arch. Biochem. Biophys. 1989, 269, 264-271.
19. Ohkawa, H., N. Ohishi & K. Yagi: Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-358.
20. Olson, R. D. & P. S. Mushlin: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB 1990, 4, 3076-3086.
21. Pacher, P., L. Liaudet, P. Bai, J. G. Mabley, P. M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M. S. Wolin et al.: Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003, 107, 896-904.
22. Pacher, P., R. Schulz, L. Liaudet & C. Szabo: Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol. Sci. 2005, 26, 302-310.
23. Paglia, D. E. & W. N. Valentine: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967, 70, 158-169.
24. Park, I. Y., E. J. Kim, H. Park, K. Fields, A. K. Dunker & C. Kang: Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. Mol. Pharmacol. 2005, 67, 97-104.
25. Pritsos, C. A., M. Sokoloff & D. L. Gustafson: PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. Biochem. Pharmacol. 1992, 44, 839-841.
26. Saad, S. Y., T. A. Najjar & A. C. Al-Rikabi: The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. Pharmacol. Res. 2001, 43, 211-218.
27. Saad, S. Y., T. A. O. Najjar & M. Alashari: Cardiotoxicity of doxorubicin/paclitaxel combination in rats: Effect of sequence and timing of administration. J. Biochem. Mol. Toxicol. 2004, 18, 78-86.
28. Sarker, K. P., K. K. Biswas, J. L. Rosales, K. Yamaji, T. Hashiguchi, K. Y. Lee & I. Maruyama: Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPKand Bcl-2. Neurochem. 2003, 87, 1345-1353.
29. Schuller, J., M. Czejka, C. Pietrzak et al.: Doxorubicin pharmacokinetics is altered differently by the cytoprotective agents amifostine or cardioxane (ICRF-187) [abstract]. Ann. Oncol. 1996, 7, 124.
30. Shadle, S. E., B. P. Bammel, B. J. Cusack, R. A. Knighton, S. J. Olson, P. S. Mushlin & R. D. Olson: Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem. Pharmacol. 2000, 60, 1435-1444.
31. Simunek, T., I. Klimtova, J. Kaplanova, Y. Mazurova, M. Adamcova, M. Sterba, R. Hrdina & V. Gersl: Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur. J. Heart Fail. 2004, 6, 377-387.
32. Simunek, T., I. Klimtova, J. Kaplanova, M. Sterba, Y. Mazurova, M. Adamcova, R. Hrdina, V. Gersl & P. Ponka: Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res. 2005, 51, 223-231.
33. Slupe, A., B. Williams, C. Larson, L. M. Lee, T. Primbs, A. J. Bruesch, C. Bjorklund, D. L. Warner, J. Peloquin, S. E. Shadle, H. A. Gambliel, B. J. Cusack, R. D. Olson & H. A. Jr. Charlier: Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc. Toxicol. 2005, 5, 365-376.
34. Vasquez-Vivar, J., P. Martasek, N. Hogg, B. S. S. Masters, K. A. Jr. Pritchard & B. Kalyanaraman: Endothelial nitric oxide syhthase-dependent superoxide generation from adriamycin. Biochemistry 1997, 36, 11293-11297.
35. Vasquez-Vivar, J., B. Kalyanaraman & M. C. Kennedy: Mitochondrial aconitase is a source of hydroxyl radical: an electron spin resonance investigation. J. Biol. Chem. 2000, 275, 14064-14069.
36. Wang, S., S. Kotamraju, E. Konorev, S. Kalivendi, J. Joseph & B. Kalyanaraman: Activation of nuclear factor kappa B during doxorubicin-induced apoptosis in endothelial cells and myocytes is proapoptotic: The role of hydrogen peroxide. Biochem. J. 2002, 367, 729-740.
37. Wu, X. & B. B. Hasinoff: The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 2005, 16, 93-99.
38. Yang, C. F., H. M. Shen & C. N. Ong: Intracellular thiol depletion causes mitochondrial permeability transition in ebselen-induced apoptosis. Arch. Biochem. Biophys. 2000, 380, 319-330.
39. Yoshizumi, M., Y. Fujita, Y. Izawa, Y. Suzaki, M. Kyaw, N. Ali, K. Tsuchiya, S. Kagami, S. Yano, S. Sone & T. Tamaki: Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cells. Exp. Cell Res. 2004, 292, 1-10.